Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chromosome 17 deletion × pomalidomide × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 40 Recurrence 10 Neoplasms, Plasma Cell 3 Sarcoma, Kaposi 2 Acquired Immunodeficiency Syndrome 2 Plasmablastic Lymphoma 1 Neoplasms 1 Multi-centric Castleman's Disease 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Immunoglobulin Light-chain Amyloidosis 1 Epstein-Barr Virus Infections 1 Chromosome 17 deletion 1 Burkitt Lymphoma 1 Alzheimer Disease 1

Interventions

venetoclax 1 pomalidomide 1 pembrolizumab 1 ibrutinib 1 fludarabine phosphate 1 fludarabine 1 acalabrutinib 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01745640 2026-02-05

IFM2010-02

University Hospital, Lille

Phase 2 Completed

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡